

FFB 02 2005

FFB 02 2005

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Approved for use through 07/31/2023. GPO 2021-183.

I understand the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for RABIE 1-9/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Shee

4

of 11

Complete if Known

Application Number	09/707,900
Filing Date	November 8, 2000
First Named Inventor	Moon Jong Noh
Art Unit	1632
Examiner Name	Michael C. Wilson
Attorney Docket Number	55293-00007

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
MM	B1	1. WO96/39196	12-12-1996	University of Pittsburgh	whole document	
MM	B2	2. WO97/25414	07-17-1997	Vandenburgh	whole document	
MM	B3	3. WO99/11789	03-11-1999	North Shore University	whole document	
MM	B4	4. WO99/56785	11-11-1999	University of Pittsburgh	whole document	

**Examiner
Signature**


Date Considered

4-3-04

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

4

Complete if Known

Application Number	09/707,900
Filing Date	November 8, 2000
First Named Inventor	Moon Jong Noh
Art Unit	1632
Examiner Name	Michael C. Wilson
Attorney Docket Number	55293-00007

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
MM	C1	CHERNAJOVSKY: Systemic gene therapy for arthritis, Drugs of Today, 35(4-5):361-377, Apr.-May 1999.
	C2	ROBBINS et al.: Gene therapy for rheumatoid arthritis, Springer Seminars in Immunopathology, 20: 197-209, 1998.
	C3	EVANS and ROBBINS: Gene therapy of arthritis, Internal Medicine, 38 (3): 233-9, Mar. 1999.
	C4	EVANS et al.: Blocking cytokines with genes, J Leucocyte Biol., 64:55-61, 1998.
	C5	MASON et al.: Expression of bone morphogenic protein 7 in primary rabbit periosteal cells: ~, Gene Therapy, 1998.
	C6	ARAI et al.: Adenovirus vector-mediated gene transduction to chondrocytes: ~ J. Rheumatol, 24:1787-1795, 1997.
	C7	OTANI et al.: Suppression of antigen induced arthritis in Rabbits by ex vivo gene therapy, J Immunol., 156:3558-3562, 1996.
	C8	ANDREW et al.: Demonstration of TGF-beta-1 mRNA by in situ hybridization in normal fracture healing. Calcif Tissue Int, 52: 74-78, 1993. (Abstract only)
	C9	BOURQUE et al.: Expression of four growth factors during fracture repair. Int J Dev Biol, 37: 573-579, 1993. (Abstract only)
MM	C10	BRAND and SCHNEIDER: Inactive type II and type I receptors: TGF-beta are dominant inhibitors of TGF-beta-dependent transcription. J Biol Chem, 270: 8274-8284, 1995.

Examiner Signature	MM	Date Considered	4-8-05
--------------------	----	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/707,900
		Filing Date	November 8, 2000
		First Named Inventor	Moon Jong Noh
		Art Unit	1632
Examiner Name	Michael C. Wilson		
Sheet 2 of 4	Attorney Docket Number 55293-00007		

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
WW	C11	BRITTBURG et al.: Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. New Engl J Med 331: 889-895, 1994.	
	C12	CARRINGTON et al.: Accumulation, localization and compartmentation of TGF-beta. during enchondral bone development. J Cell Biology, 107: 1969 1975, 1988.	
	C13	CENTRELLA et al.: Human platelet-derived transforming growth factor-beta. stimulates parameters of bone growth in fetal rat calvariae. Endocrinology, 119: 2306-2312, 1986.	
	C14	CHEIFETZ et al.: Transforming growth factor beta system, a complex pattern of cross-reactive ligands and receptors. Cell, 48: 409-415, 1987.	
	C15	CHENU et al.: TGF-beta inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc Natl Acad Sci, 85: 5683-5687, 1988.	
	C16	CRITCHLOW et al.: The effect of exogenous transforming growth factor. Beta.2 on healing fractures in the rabbit. Bone, 521-527, 1995.	
	C17	DALLAS et al.: Dual role for the latent transforming growth factor beta binding protein in storage of latent TGF-beta. J Cell Biol, 131: 539-549, 1995.	
	C18	DUMONT et al.: Transforming growth factor receptors on human endometrial cells: identification of the type I and II receptors ~. M Cell Endo, 111: 57-66, 1995.	
	C19	FRENKEL et al.: Chondrocyte transplantation using a collagen bilayer matrix for cartilage repair. J Bone J Surg [Br] 79-B: 831-836, 1997. (Abstract only)	
WW	C20	HEINE et al.: Role of Transforming Growth Factor-beta in the development of the mouse embryo. Cell Biology, 105: 2861-2876, 1987.	

Examiner Signature	WW	Date Considered	4-8-05
--------------------	----	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	09/707,900
		Filing Date	November 8, 2000
		First Named Inventor	Moon Jong Noh
		Art Unit	1632
		Examiner Name	Michael C. Wilson
Sheet 3 of 4	Attorney Docket Number	55293-00007	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MCN	C21	JOYCE et al.: Transforming Growth Factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biology, 110: 2195-2207, 1990.	
	C22	LIND et al.: Transforming growth factor-beta enhances fracture healing in rabbit tibiae. A Orthop Scand, 64(5): 553-556, 1993. (Abstract only)	
	C23	LOPEZ-CASILLAS et al.: Structure and expression of the membrane proteoglycan component of the TGF-beta receptor system. Cell, 67: 785-795, 1991.	
	C24	MADRI et al.: Phenotypic modulation of endothelial cells by Transforming Growth-. Depends upon the composition and organization of-. J Cell Biology, 106: 1375- 1384, 1988.	
	C25	MASSAGUE: TGF-Beta Signal Transduction Ann. Rev. Biochem. 67:753-791, 1998.	
	C26	MATSUMOTO et al.: Expression and Distribution of Transforming Growth Factor-beta. During Fracture Healing. In vivo, 8: 215-220, 1994. (Abstract only)	
	C27	MEERT et al: Elevated Transforming Growth Factor-beta Concentration ~, The Journal of Trauma, Injury, Infection and Critical Care, vol. 40, No. 6, pp. 901-906, 1996.	
	C28	MIETTINEN et al.: TGF-beta Induced Transdifferentiation of Mammary Epithelial Cells ~: Involvement of Type I Receptors. J Cell Biology, 127-6: 2021-2036, 1994.	
	C29	OZKAYNAK et al.: OP-1 cDNA Encodes an Osteogenic Protein in the TGF-beta Family. EMBO J, 9: 2085-2093, 1990. (Abstract only)	
MCN	C30	SPORN and ROBERTS: Peptide Growth Factors are Multifunctional. Nature (London), 332: 217-219, 1988. (Abstract only)	

Examiner Signature	<i>MCN</i>	Date Considered	4-8-05
--------------------	------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

FEB 02 2005

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete If Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

4

Application Number

09/707,900

Filing Date

November 8, 2000

First Named Inventor

Moon Jong Noh

Art Unit

1632

Examiner Name

Michael C. Wilson

Attorney Docket Number

55293-00007

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MM	C31	WAKEFIELD et al.: Latent Transforming Growth Factor-beta from Human Platelets. J Biol Chem, 263: 7646-7654, 1988.	
	C32	WRANA et al.: Mechanism of Activation of the TGF-beta Receptor. Nature, 370: 341-347, 1994. (Abstract only)	
	C33	SONG et al.: Plasmid DNA Encoding Transforming~, J. Clin. Investigation, 101: 2615-2621, Jun. 15, 1998.	
	C34	SITTINGER et al.: Joint cartilage regeneration by tissue engineering, Zeitschrift fuer Rheumatologie. 58(3): 130-135, Jun. 1999.	
	C35	PRUD'HOMME et al.: Anticytokine Gene Therapy of Autoimmune Diseases. Exp. Opin. Biol. Ther, 1(3):359-373, 2001.	
	C36	MOLLER et al.: TGF-beta-1 gentransfer in gelenknopzellen (TGF beta-1 gene transfer in articular chondrocytes). Orthopade, 29(2): 75-9, Feb. 2000. (English abstract)	✓
MM	C37	MOLLER and EVANS, Genetherapeutische Ansatze in der Arthrosebehandlung (Gene transfer in the treatment of arthritis), Orthopade, 28(1): 76-81, Jan. 1999. (English abstract)	✓
	C38		
	C39		
	C40		

Examiner
Signature*MM*Date
Considered

4-8-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.